Cereblon as the cellular target responsible for the anti-multiple myeloma activity of immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F14%3A00011083" target="_blank" >RIV/00023736:_____/14:00011083 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cereblon as the cellular target responsible for the anti-multiple myeloma activity of immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide)

Popis výsledku v původním jazyce

The binding of immunomodulatory drugs (IMiDs) to CRBN is associated with cytotoxicity of IMiDs and is used to treat multiple myeloma (MM), myelodysplastic syndromes (MDS) and lymphomas. The CRBN gene consists of 1329 base pairs, 11 exons, and encodes a protein of 443 amino acids. Exons 10-11 code for binding site of IMiDs and exons 5-7 for binding site of DDB1. CRBN plays a key role in mediating the antiproliferative and immunomodulatory activities of IMiDs in MM cells and T cells, respectively. Two target proteins, the zinc finger-containing transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) have been recently revealed by analysis of MM cell lines treated with lenalidomide.

Název v anglickém jazyce

Cereblon as the cellular target responsible for the anti-multiple myeloma activity of immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide)

Popis výsledku anglicky

The binding of immunomodulatory drugs (IMiDs) to CRBN is associated with cytotoxicity of IMiDs and is used to treat multiple myeloma (MM), myelodysplastic syndromes (MDS) and lymphomas. The CRBN gene consists of 1329 base pairs, 11 exons, and encodes a protein of 443 amino acids. Exons 10-11 code for binding site of IMiDs and exons 5-7 for binding site of DDB1. CRBN plays a key role in mediating the antiproliferative and immunomodulatory activities of IMiDs in MM cells and T cells, respectively. Two target proteins, the zinc finger-containing transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) have been recently revealed by analysis of MM cell lines treated with lenalidomide.

Druh

C - Kapitola v odborné knize

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13836" target="_blank" >NT13836: Studium patogeneze myelodysplastického syndromu u pacientů s izolovanou aberací del(5q) a analýza účinku lenalidomidu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Multiple myeloma: risk factors, diagnosis and treatments

ISBN

978-1-63321-514-6

Počet stran výsledku

20

Strana od-do

81-100

Počet stran knihy

118

Název nakladatele

Nova Biomedical

Místo vydání

New York

Kód UT WoS kapitoly

—